The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Open accessAbstract
Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, these gains can come at a cost. Patients may experience adverse cardiovascular events related to their cancer treatment or as a result of an exacerbation of underlying cardiovascular disease. With longer periods of survival, late effects of cancer treatment may become clinically evident years or decades after completion of therapy. Current cancer therapy incorporates multiple agents whose deleterious cardiac effects may be additive or synergistic. Cardiac dysfunction may result from agents that can result in myocyte destruction, such as with anthracycline use, or from agents that appear to transiently affect left ventricular contractility. In addition, cancer treatment may be associated with other cardiac events, such as severe treatment‐induced hypertension and vasospastic and thromboembolic ischemia, as well as rhythm disturbances, including QTc prolongation, that may be rarely life‐threatening. Early and late effects of chest radiation can lead to radiation‐induced heart disease, including pericardial disease, myocardial fibrosis, cardiomyopathy, coronary artery disease, valvular disease, and arrhythmias, in the setting of myocardial fibrosis. The discipline of cardio‐oncology has developed in response to the combined decision making necessary to optimize the care of cancer patients, whether they are receiving active treatment or are long‐term survivors. Strategies to prevent or mitigate cardiovascular damage from cancer treatment are needed to provide the best cancer care. This review will focus on the common cardiovascular issues that may arise during or after cancer therapy, the detection and monitoring of cardiovascular injury, and the best management principles to protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies. CA Cancer J Clin 2016;66:309‐325. © 2016 American Cancer Society .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Recommendations for the evaluation of left ventricular diastolic function by echocardiography
Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., Waggoner, A. D., Flachskampf, F. A., Pellikka, P. A., & Evangelisa, A. (2008) · European Journal of Echocardiography · doi:10.1093/ejechocard/jep007 · Cited by 3,351
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Self-citationEarly Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Self-citationSmith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Radiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Self-citationCardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Thavendiranathan, P., Poulin, F., Lim, K.-D., Plana, J. C., Woo, A., & Marwick, T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.073 · Cited by 1,079
Cardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Self-citationMechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Trends in the Leading Causes of Death in the United States, 1970-2002
Jemal, A. (2005) · JAMA · doi:10.1001/jama.294.10.1255 · Cited by 987
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Self-citationAdjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Self-citationCardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Self-citationSawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Self-citationPerez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.035 · Cited by 689
Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., Gosavi, S., Carver, J. R., Wiegers, S. E., Martin, R. P., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.01.006 · Cited by 682
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Self-citationPinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Consequences of Brief Ischemia: Stunning, Preconditioning, and Their Clinical Implications: Part 1
Kloner, R. A., & Jennings, R. B. (2001) · Circulation · doi:10.1161/hc4801.100038 · Cited by 634
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M., Morales-Ruiz, M., Perea, R. J., Monzó, M., & Esteve, J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.072 · Cited by 632
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., & Schmidinger, H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6331 · Cited by 615
Armstrong, G. T., Kawashima, T., Leisenring, W., Stratton, K., Stovall, M., Hudson, M. M., Sklar, C. A., Robison, L. L., & Oeffinger, K. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1055 · Cited by 584
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 563
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Self-citationHensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
Mandalà, M., Falanga, A., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr392 · Cited by 512
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
Gottdiener, J. S. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.141.6.758 · Cited by 486
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
Cancer drugs and the heart: importance and management
Suter, T. M., & Ewer, M. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs181 · Cited by 472
Wouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data
Howlader, N., Ries, L. A. G., Mariotto, A. B., Reichman, M. E., Ruhl, J., & Cronin, K. A. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq366 · Cited by 452
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Moslehi, J. J., & Deininger, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4718 · Cited by 443
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Asymptomatic cardiac disease following mediastinal irradiation
Heidenreich, P. A., Hancock, S. L., Lee, B. K., Mariscal, C. S., & Schnittger, I. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00759-9 · Cited by 393
Cardiotoxicity of cytotoxic drugs
Schimmel, K. J. M., Richel, D. J., van den Brink, R. B. A., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.003 · Cited by 391
Drafts, B. C., Twomley, K. M., D'Agostino, R., Lawrence, J., Avis, N., Ellis, L. R., Thohan, V., Jordan, J., Melin, S. A., Torti, F. M., et al. (2013) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2012.11.017 · Cited by 391
Farmakis, D., Parissis, J., & Filippatos, G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.026 · Cited by 387
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 384
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
Goldberg, M., Antin, J., Guinan, E., & Rappeport, J. (1986) · Blood · doi:10.1182/blood.v68.5.1114.1114 · Cited by 371
Force, T., & Kolaja, K. L. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3252 · Cited by 363
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Chen, J., Long, J. B., Hurria, A., Owusu, C., Steingart, R. M., & Gross, C. P. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.068 · Cited by 352
Kalam, K., & Marwick, T. H. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.030 · Cited by 343
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.033 · Cited by 340
Erratum: Cardiotoxicity of anticancer treatments
Ewer, M. S., & Ewer, S. M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.133 · Cited by 340
Jensen, B. V., Skovsgaard, T., & Nielsen, S. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf132 · Cited by 336
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8332 · Cited by 332
Seicean, S., Seicean, A., Plana, J. C., Budd, G. T., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.067 · Cited by 326
Kaya, M. G., Ozkan, M., Gunebakmaz, O., Akkaya, H., Kaya, E. G., Akpek, M., Kalay, N., Dikilitas, M., Yarlioglues, M., Karaca, H., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.06.023 · Cited by 325
Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3404 · Cited by 323
Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms
Taunk, N. K., Haffty, B. G., Kostis, J. B., & Goyal, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00039 · Cited by 316
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Self-citationConsequences of Brief Ischemia: Stunning, Preconditioning, and Their Clinical Implications: Part 2
Kloner, R. A., & Jennings, R. B. (2001) · Circulation · doi:10.1161/hc5001.100039 · Cited by 286
Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Hahn, V. S., Lenihan, D. J., & Ky, B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000665 · Cited by 264
Self-citationProtective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy
Akpek, M., Ozdogru, I., Sahin, O., Inanc, M., Dogan, A., Yazici, C., Berk, V., Karaca, H., Kalay, N., Oguzhan, A., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.196 · Cited by 258
European Society of Cardiology Heart Failure Association Standards for Delivering Heart Failure Care
McDonagh, T. A., Blue, L., Clark, A. L., Dahlström, U., Ekman, I., Lainscak, M., McDonald, K., Ryder, M., Strömberg, A., & Jaarsma, T. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq221 · Cited by 257
Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demir, S., Meriç, M., & Ağaç, M. T. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.025 · Cited by 255
Negishi, K., Negishi, T., Haluska, B. A., Hare, J. L., Plana, J. C., & Marwick, T. H. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet159 · Cited by 245
Procter, M., Suter, T. M., de Azambuja, E., Dafni, U., van Dooren, V., Muehlbauer, S., Climent, M. A., Rechberger, E., Liu, W. T.-W., Toi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0463 · Cited by 244
Kim, T. D., Rea, D., Schwarz, M., Grille, P., Nicolini, F. E., Rosti, G., Levato, L., Giles, F. J., Dombret, H., Mirault, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.70 · Cited by 233
Declining Death Rates Reflect Progress against Cancer
Jemal, A., Ward, E., & Thun, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009584 · Cited by 230
Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer
Baselga, J., Perez, E. A., Pienkowski, T., & Bell, R. (2006) · The Oncologist · doi:10.1634/theoncologist.11-90001-4 · Cited by 222
Giles, F. J., Mauro, M. J., Hong, F., Ortmann, C.-E., McNeill, C., Woodman, R. C., Hochhaus, A., le Coutre, P. D., & Saglio, G. (2013) · Leukemia · doi:10.1038/leu.2013.69 · Cited by 216
Introducing a new entity: chemotherapy-induced arrhythmia
Guglin, M., Aljayeh, M., Saiyad, S., Ali, R., & Curtis, A. B. (2009) · Europace · doi:10.1093/europace/eup300 · Cited by 214
Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?
Ewer, M. S., & Lenihan, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8742 · Cited by 207
Self-citationPretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice
Riad, A., Bien, S., Westermann, D., Becher, P. M., Loya, K., Landmesser, U., Kroemer, H. K., Schultheiss, H. P., & Tschöpe, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3076 · Cited by 205
The utility of troponin measurement to detect myocardial infarction: review of the current findings
Jeremias, A. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5306 · Cited by 204
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben-Yehuda, O., & Moslehi, J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 201
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C. J., Stanley, A., & Verrill, M. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn728 · Cited by 196
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Cheng, H., & Force, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.206920 · Cited by 192
Chintalgattu, V., Ai, D., Langley, R. R., Zhang, J., Bankson, J. A., Shih, T. L., Reddy, A. K., Coombes, K. R., Daher, I. N., Pati, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39434 · Cited by 188
Kenmotsu, H., & Tanigawara, Y. (2015) · Cancer Science · doi:10.1111/cas.12647 · Cited by 176
Cardiovascular disease after cancer therapy
Aleman, B. M. P., Moser, E. C., Nuver, J., Suter, T. M., Maraldo, M. V., Specht, L., Vrieling, C., & Darby, S. C. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.002 · Cited by 168
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity
Kilickap, S., Barista, I., Akgul, E., Aytemir, K., Aksoyek, S., Aksoy, S., Celik, I., Kes, S., & Tekuzman, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi152 · Cited by 167
Seicean, S., Seicean, A., Alan, N., Plana, J. C., Budd, G. T., & Marwick, T. H. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000055 · Cited by 165
Cadeddu, C., Piras, A., Mantovani, G., Deidda, M., Dessì, M., Madeddu, C., Massa, E., & Mercuro, G. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.05.037 · Cited by 159
Perez, E. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-6-373 · Cited by 152
Morris, P. G., Chen, C. C. L., Steingart, R. M., Fleisher, M., Lin, N., Moy, B., Come, S. E., Sugarman, S. M., Abbruzzi, A., Lehman, R. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1359 · Cited by 143
Mackey, J. R., Clemons, M. J., Côté, M. A., Delgado, D., Dent, S. F., Paterson, A., Provencher, L., Sawyer, M. B., & Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.199 · Cited by 142
Self-citationGrandin, E. W., Ky, B., Cornell, R. F., Carver, J. R., & Lenihan, D. J. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.11.008 · Cited by 130
Self-citationUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity
Christenson, E. S., James, T., Agrawal, V., & Park, B. H. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.10.013 · Cited by 128
Sandri, M. T., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., Martinoni, A., Martinelli, G., & Cipolla, C. M. (2003) · Clinical Chemistry · doi:10.1373/49.2.248 · Cited by 123
Self-citationIdarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Anderlini, P. N., Benjamin, R. S., Wong, F. C. S., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2827 · Cited by 123
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
Lenihan, D. J., Suter, T. M., Brammer, M. G., Neate, C., Ross, G. A., & Baselga, J. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr294 · Cited by 120
Self-citationCardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
Atrash, S., Tullos, A., Panozzo, S. B., Bhutani, M., van Rhee, F., Barlogie, B., & Usmani, S. Z. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2014.93 · Cited by 114
Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure
Tallaj, J. A., Franco, V., Rayburn, B. K., Pinderski, L. J., Benza, R. L., Pamboukian, S. V., Foley, B. A., & Bourge, R. C. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.12.108 · Cited by 100
Mornoş, C., & Petrescu, L. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0398 · Cited by 96
Langenberg, M. H. G., van Herpen, C. M. L., Bono, J. S. D., Schellens, J. H. M., Unger, C., Hoekman, K., Blum, H. E., Fiedler, W., Drevs, J., Maulf, F. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2273 · Cited by 95
Pituskin, E., Haykowsky, M. J., Mackey, J. R., Thompson, R. B., Ezekowitz, J. A., Koshman, S. L., Oudit, G. Y., Chow, K., Pagano, J. J., & Paterson, D. I. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-318 · Cited by 89
George, S., Reichardt, P., Lechner, T., Li, S., Cohen, D. P., & Demetri, G. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds179 · Cited by 86
Adriamycin (doxorubicin) cardiotoxicity: a review.
Chlebowski, R. T. (1979) · PubMed · Cited by 84
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
Tascilar, M., Loos, W. J., Seynaeve, C., Verweij, J., & Sleijfer, S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-11-1351 · Cited by 82
Reversibility of Severe Left Ventricular Dysfunction Due to Doxorubicin Cardiotoxicity
Saini, J., RICH, M. W., & LYSS, A. P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-814 · Cited by 79
Late doxorubicin-associated cardiotoxicity in children
Ali, M. K., Ewer, M. S., Gibbs, H. R., Swafford, J., & Graff, K. L. (1994) · Cancer · Cited by 77
Braña, I., & Tabernero, J. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq295 · Cited by 75
Daneault, B., Généreux, P., Kirtane, A. J., Witzenbichler, B., Guagliumi, G., Paradis, J., Fahy, M. P., Mehran, R., & Stone, G. W. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.040 · Cited by 63
Incidence of New‐Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
Fraeman, K. H., Nordstrom, B. L., Luo, W., Landis, S., & Shantakumar, S. (2013) · International Journal of Hypertension · doi:10.1155/2013/379252 · Cited by 61
Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis
Thakur, A., & Witteles, R. M. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.12.018 · Cited by 59
Thrombosis in multiple myeloma (MM)
Cesarman-Maus, G. N., Braggio, E., & Fonseca, R. (2012) · Hematology · doi:10.1179/102453312x13336169156933 · Cited by 53
Brell, J. M. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.005 · Cited by 50
Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity
Lee, H. S., Son, C. B., Shin, S. H., & Kim, Y. S. (2008) · Cancer Research and Treatment · doi:10.4143/crt.2008.40.3.121 · Cited by 48
Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Tjuljandin, S. A., Doig, R. G., Sobol, M. M., Watson, D. M., Sheridan, W. P., Morstyn, G., Mihaly, G. W., & Green, M. D. (1990) · PubMed · Cited by 48
Gampenrieder, S. P., Romeder, F., Muß, C., Pircher, M., Ressler, S., Rinnerthaler, G., Bartsch, R., Sattlberger, C., Mlineritsch, B., & Greil, R. (2014) · PubMed · Cited by 42
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy
Harbeck, N., Ewer, M. S., Laurentiis, M. D., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq543 · Cited by 41
Dewdney, A., Cunningham, D., Barbáchano, Y., & Chau, I. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.152 · Cited by 35
Cardiac Complications of Chemotherapy: Role of Biomarkers
Colombo, A., Sandri, M. T., Salvatici, M., Cipolla, C. M., & Cardinale, D. M. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0313-6 · Cited by 32
Self-citationZheng, Y., Chen, J., & Lu, Y. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s87258 · Cited by 31
Ky, B., & Carver, J. R. (2011) · Heart Failure Clinics · doi:10.1016/j.hfc.2011.03.002 · Cited by 31
Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents
Larochelle, P. M., Kollmannsberger, C., Feldman, R. D., Schiffrin, E. L., Poirier, L., Patenaude, F., Ruether, D., Myers, M. G., & Bjarnason, G. A. (2012) · Current Oncology · doi:10.3747/co.19.972 · Cited by 30
Clinical guide SEOM on venous thromboembolism in cancer patients
Martín, A. J. M., Font, C., Martín, L. M. N., et al. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1238-y · Cited by 29
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
Lebedinsky, C. A., Gómez, J., Park, Y. C., Nieto, A., Soto-Matos, A., Parekh, T. V., Alfaro, V., Roy, E., Lardelli, P., & Kahatt, C. M. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1614-z · Cited by 27
Cancer and Cardiovascular Disease: The Complex Labyrinth
Dent, S. F., Liu, P. X., Brezden‐Masley, C., & Lenihan, D. J. (2015) · Journal of Oncology · doi:10.1155/2015/516450 · Cited by 23
Self-citationPrecision medicine and personalized breast cancer: combination pertuzumab therapy
Dizon, D. S., Reynolds, K., Sarangi, S., & Bardia, A. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s37100 · Cited by 21
Geiger, S., Stemmler, H., Suhl, P., Stieber, P., Lange, V., Baur, D. M., Hausmann, A., Tischer, J., & Horster, S. (2012) · Onkologie · doi:10.1159/000338335 · Cited by 15
Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
Ševčíková, K., Vertáková-Krakovská, B., & Spanik, S. (2013) · ISRN Oncology · doi:10.1155/2013/362467 · Cited by 11
Cited by
CAMPBELL, K. L., WINTERS-STONE, K. M., WISKEMANN, J., MAY, A. M., SCHWARTZ, A. L., COURNEYA, K. S., ZUCKER, D. S., MATTHEWS, C. E., LIGIBEL, J. A., GERBER, L. H., et al. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002116 · Cited by 2,988
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
Self-citationRawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Self-citation
Metadata
- Authors
- Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2016-02-26
- Volume
- 66
- Issue
- 4
- Pages
- 309-325
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2279656465
- Cited by
- 723
- References
- 140
- FWCI
- 37.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.